Sandra J Casak

8PUBLICATIONS
47CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 05, 2026
FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal.

|Mar 06, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.

Sandra J Casak, Yiming Zhang, Chi Song

|Jun 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.

Sandra J Casak, Vaibhav Kumar, Chi Song

|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.

Michael J Fusco, Sandra J Casak, Sirisha L Mushti

|Jun 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.

Sandra J Casak, M Naomi Horiba, Mengdie Yuan

|Jun 08, 2023
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.

Shruti U Gandhy, Sandra J Casak, Sirisha L Mushti

Pageof 2

Frequent Collaborators

7 joint publications

Steven J Lemery

6 joint publications

Lola A Fashoyin-Aje

6 joint publications

Doris Auth

6 joint publications

Richard Pazdur